CY1105456T1 - Χρηση σκιαγραφικων αντιδραστηριων στην παρασκευη ενος διαγνωστικου αντιδραστηριου για την απεικονιση του εντepικου αυλου - Google Patents

Χρηση σκιαγραφικων αντιδραστηριων στην παρασκευη ενος διαγνωστικου αντιδραστηριου για την απεικονιση του εντepικου αυλου

Info

Publication number
CY1105456T1
CY1105456T1 CY20061100565T CY061100565T CY1105456T1 CY 1105456 T1 CY1105456 T1 CY 1105456T1 CY 20061100565 T CY20061100565 T CY 20061100565T CY 061100565 T CY061100565 T CY 061100565T CY 1105456 T1 CY1105456 T1 CY 1105456T1
Authority
CY
Cyprus
Prior art keywords
lurma
entepical
imaging
preparation
diagnostic reagent
Prior art date
Application number
CY20061100565T
Other languages
Greek (el)
English (en)
Inventor
Michael V. KNOO
Frederik Giesel
Hendrik Von Tengg-Kobligk
Jannis Radeleff
Original Assignee
Bracco Imaging S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1999MI002735 external-priority patent/IT1315273B1/it
Priority claimed from IT2000MI000193A external-priority patent/IT1317816B1/it
Application filed by Bracco Imaging S.P.A. filed Critical Bracco Imaging S.P.A.
Publication of CY1105456T1 publication Critical patent/CY1105456T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CY20061100565T 1999-12-29 2006-05-02 Χρηση σκιαγραφικων αντιδραστηριων στην παρασκευη ενος διαγνωστικου αντιδραστηριου για την απεικονιση του εντepικου αυλου CY1105456T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI002735 IT1315273B1 (it) 1999-12-29 1999-12-29 Imaging del colon mediante contrastografia.
IT2000MI000193A IT1317816B1 (it) 2000-02-08 2000-02-08 Imaging del colon mediante contrastografia.
PCT/EP2000/013069 WO2001049326A1 (en) 1999-12-29 2000-12-21 Use of contrast agents in the manufacture of diagnostic agent for the visualisation of the intestinal lumen

Publications (1)

Publication Number Publication Date
CY1105456T1 true CY1105456T1 (el) 2010-04-28

Family

ID=26331700

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100565T CY1105456T1 (el) 1999-12-29 2006-05-02 Χρηση σκιαγραφικων αντιδραστηριων στην παρασκευη ενος διαγνωστικου αντιδραστηριου για την απεικονιση του εντepικου αυλου

Country Status (12)

Country Link
US (1) US20030113267A1 (https=)
EP (1) EP1251875B1 (https=)
JP (1) JP4798919B2 (https=)
CN (1) CN1302814C (https=)
AT (1) ATE320272T1 (https=)
AU (1) AU2842901A (https=)
CY (1) CY1105456T1 (https=)
DE (1) DE60026743T2 (https=)
DK (1) DK1251875T3 (https=)
ES (1) ES2259299T3 (https=)
PT (1) PT1251875E (https=)
WO (1) WO2001049326A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7606347B2 (en) * 2004-09-13 2009-10-20 General Electric Company Photon counting x-ray detector with overrange logic control
US7260174B2 (en) 2004-09-13 2007-08-21 General Electric Company Direct conversion energy discriminating CT detector with over-ranging correction
US7599465B2 (en) 2004-11-19 2009-10-06 General Electric Company Detection of thrombi in CT using energy discrimination
US7209536B2 (en) * 2004-11-19 2007-04-24 General Electric Company CT colonography system
US7583779B2 (en) * 2004-11-24 2009-09-01 General Electric Company System and method for acquisition and reconstruction of contrast-enhanced, artifact-reduced CT images
US7382853B2 (en) * 2004-11-24 2008-06-03 General Electric Company Method and system of CT data correction
US7613274B2 (en) * 2007-11-16 2009-11-03 General Electric Company Method and system of energy integrating and photon counting using layered photon counting detector
ES2955349T3 (es) * 2019-09-18 2023-11-30 Bayer Ag Predicción de imágenes MRI mediante un modelo de predicción entrenado por aprendizaje supervisado
JP7587575B2 (ja) * 2019-10-08 2024-11-20 バイエル、アクチエンゲゼルシャフト コントラスト強調のない肝臓のｍｒｉ画像の生成

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999445A (en) * 1988-06-10 1991-03-12 The Regents Of The University Of California Contrast agents for magnetic resonance imaging of the small intestine and hepatobiliary system
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5245282A (en) * 1991-06-28 1993-09-14 University Of Virginia Alumni Patents Foundation Three-dimensional magnetic resonance imaging
WO1993003351A1 (en) * 1991-08-09 1993-02-18 The Regents Of The University Of California Amino acid, ester and/or catechol contrast agents for mri
IT1252145B (it) * 1991-11-29 1995-06-05 Bracco Ind Chimica Spa Metodo e formulazioni adatte a migliorare lo studio degli organi cavi nell'uomo
WO1993015093A1 (en) * 1992-01-29 1993-08-05 The Regents Of The University Of California Specific contrast agents for magnetic resonance imaging of the small intestine and hepatobiliary system
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
IT1269839B (it) * 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
JP4432000B2 (ja) * 1996-12-23 2010-03-17 ブラッコ・リサーチ・ソシエテ・アノニム 患者の消化管の視覚化におけるｍｒｉ造影の増加用組成物

Also Published As

Publication number Publication date
WO2001049326A1 (en) 2001-07-12
ATE320272T1 (de) 2006-04-15
PT1251875E (pt) 2006-07-31
DK1251875T3 (da) 2006-07-24
EP1251875B1 (en) 2006-03-15
EP1251875A1 (en) 2002-10-30
US20030113267A1 (en) 2003-06-19
JP2003519200A (ja) 2003-06-17
DE60026743D1 (de) 2006-05-11
DE60026743T2 (de) 2006-08-17
JP4798919B2 (ja) 2011-10-19
AU2842901A (en) 2001-07-16
ES2259299T3 (es) 2006-10-01
CN1413119A (zh) 2003-04-23
CN1302814C (zh) 2007-03-07

Similar Documents

Publication Publication Date Title
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
CY1105456T1 (el) Χρηση σκιαγραφικων αντιδραστηριων στην παρασκευη ενος διαγνωστικου αντιδραστηριου για την απεικονιση του εντepικου αυλου
NO20014769D0 (no) Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
BR0110748A (pt) Plataforma de nanodispositivo multifuncional
NL300736I2 (https=)
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
EP1414499A4 (en) Non-invasive tumor imaging by tumor-targeted bacteria
CL2004001126A1 (es) Complejos de polimeros en cascada y sus composiciones farmaceuticas, utiles para la preparacion de agentes de diagnostico por nmr.
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
DK0806968T3 (da) Diagnostiske billeddannelseskontrastmidler med foröget blodretention
ATE400813T1 (de) Tumormarker für frühes krebsstadium
Walker Jr et al. Nephrotoxic and ototoxic agents
Rovetta et al. Chondroitin sulfate in erosive osteoarthritis of the hands
CY1109744T1 (el) Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων
NO964451L (no) Röntgenkontrastblandinger inneholdende farmasöytisk akseptable leirer
Bellat et al. A urinary drug-disposing approach as an alternative to intravesical chemotherapy for treating nonmuscle invasive bladder cancer
Ehrig et al. A case of'green urine'.
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
Davidson et al. The clinically negative neck in patients with early oral cavity carcinoma: a decision-analysis approach to management
CN205598411U (zh) 一种消化内科用导丝胃镜上药器
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
Gajda et al. Diagnostic value of urine cytology and urine carcinoembryonic antigen (CEA) level in the distinction between bladder cancer and urinary tract infection